Monogenic cerebral small‐vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology
Top Cited Papers
- 20 March 2020
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 27 (6), 909-927
- https://doi.org/10.1111/ene.14183
Abstract
Background and purpose Guidelines on monogenic cerebral small‐vessel disease (cSVD) diagnosis and management are lacking. Endorsed by the Stroke and Neurogenetics Panels of the European Academy of Neurology, a group of experts has provided recommendations on selected monogenic cSVDs, i.e. cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), autosomal dominant High Temperature Requirement A Serine Peptidase 1 (HTRA1), cathepsin‐A‐related arteriopathy with strokes and leukoencephalopathy (CARASAL), pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL), Fabry disease, mitochondrial encephalopathy, lactic acidosis and stroke‐like episodes (MELAS) and type IV collagen (COL4)A1/2. Methods We followed the Delphi methodology to provide recommendations on several unanswered questions related to monogenic cSVD, including genetic testing, clinical and neuroradiological diagnosis, and management. Results We have proposed ‘red‐flag’ features suggestive of a monogenic disease. General principles applying to the management of all cSVDs and specific recommendations for the individual forms of monogenic cSVD were agreed by consensus. Conclusions The results provide a framework for clinicians involved in the diagnosis and management of monogenic cSVD. Further multicentre observational and treatment studies are still needed to increase the level of evidence supporting our recommendations.Keywords
This publication has 44 references indexed in Scilit:
- The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1–6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7–34 pathogenic variantGenetics in Medicine, 2018
- Clinical correlates of longitudinal MRI changes in CADASILJournal of Cerebral Blood Flow & Metabolism, 2018
- Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspectsBMC Medicine, 2017
- CADASIL: Migraine, Encephalopathy, Stroke and Their Inter-RelationshipsPLOS ONE, 2016
- The minimum prevalence of CADASIL in northeast EnglandNeurology, 2012
- Clinical Spectrum of CADASIL and the Effect of Cardiovascular Risk Factors on PhenotypeStroke, 2010
- CADASILThe Lancet Neurology, 2009
- Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASILThe Lancet Neurology, 2008
- Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosisThe Lancet, 2001
- Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementiaNature, 1996